Companies › Quell Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Gastroenterology, Immunology; next expected readout Aug 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| QEL-005 autologous CAR-T regulatory cell therapy targeting CD19 on B cells | – | Phase 1 | Diffuse Cutaneous Systemic Sclerosis | Aug 2028 |
| QEL-001 CAR-Treg (chimeric antigen receptor-engineered regulatory T cell) targeting HLA-A2 | HLA-A2 | Phase 1 | Rejection; Transplant, Liver | Sep 2040 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07473154 | QEL-005 | Phase 1 | Diffuse Cutaneous Systemic Sclerosis | Immunology | Aug 2028 |
| NCT05234190 | QEL-001 | Phase 1 | Rejection; Transplant, Liver | Gastroenterology | Sep 2040 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.